Ventyx Biosciences (NASDAQ:VTYX) Releases Earnings Results, Beats Expectations By $0.08 EPS

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) posted its earnings results on Tuesday. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08, Briefing.com reports. During the same period last year, the company posted ($0.62) earnings per share.

Ventyx Biosciences Trading Down 5.3 %

NASDAQ:VTYX traded down $0.41 during trading hours on Thursday, hitting $7.36. 1,585,114 shares of the company were exchanged, compared to its average volume of 5,216,632. The stock has a market capitalization of $434.61 million, a price-to-earnings ratio of -2.35 and a beta of -1.06. Ventyx Biosciences has a one year low of $1.87 and a one year high of $47.25. The company has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $13.27.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on VTYX shares. Stifel Nicolaus downgraded Ventyx Biosciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research report on Tuesday, November 7th. Morgan Stanley downgraded Ventyx Biosciences from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $46.00 to $6.00 in a research report on Tuesday, November 7th. Lifesci Capital upgraded Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday. Wells Fargo & Company cut Ventyx Biosciences from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $77.00 to $8.00 in a research note on Tuesday, November 7th. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 target price (down from $43.00) on shares of Ventyx Biosciences in a research note on Friday, November 10th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $27.86.

Get Our Latest Analysis on Ventyx Biosciences

Insider Buying and Selling

In other Ventyx Biosciences news, CEO Raju Mohan sold 58,860 shares of the stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $2.12, for a total transaction of $124,783.20. Following the completion of the sale, the chief executive officer now directly owns 1,570,719 shares in the company, valued at approximately $3,329,924.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider John Nuss sold 17,628 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $2.12, for a total value of $37,371.36. Following the completion of the sale, the insider now directly owns 262,118 shares in the company, valued at approximately $555,690.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Raju Mohan sold 58,860 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $2.12, for a total value of $124,783.20. Following the completion of the sale, the chief executive officer now owns 1,570,719 shares of the company’s stock, valued at $3,329,924.28. The disclosure for this sale can be found here. 24.39% of the stock is owned by corporate insiders.

Institutional Trading of Ventyx Biosciences

Several large investors have recently made changes to their positions in VTYX. Legal & General Group Plc boosted its stake in Ventyx Biosciences by 152.3% during the 2nd quarter. Legal & General Group Plc now owns 2,422 shares of the company’s stock valued at $30,000 after purchasing an additional 1,462 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Ventyx Biosciences during the 4th quarter valued at about $32,000. Schroder Investment Management Group acquired a new position in Ventyx Biosciences during the 4th quarter valued at about $37,000. UBS Group AG acquired a new position in Ventyx Biosciences during the 4th quarter valued at about $40,000. Finally, Prelude Capital Management LLC bought a new position in shares of Ventyx Biosciences during the 4th quarter worth approximately $69,000.

About Ventyx Biosciences

(Get Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

See Also

Earnings History for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.